AGMB
AgomAb Therapeutics NV
8.60$
-1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| – | +20.2% | +69.6% | +20.5% | -25.5% | |
| – | +30.6% | +96.2% | +24.6% | -30.3% | |
| – | -48.4% | +342.4% | +40.1% | -49.6% | |
| – | – | – | – | – | |
| – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +17.4% | |
| – | +0.0% | +0.0% | +0.0% | +17.4% | |
| – | -16.5% | -42.9% | -7.8% | +24.8% | |
| – | -11.8% | -63.4% | -16.2% | +103.7% | |
| – | – | – | – | – | |
| – | +266.5% | +75.3% | -12.9% | +28.2% | |
| – | – | – | – | – | |
| – | +56.4% | +128.6% | +24.2% | -30.4% | |
| – | – | – | – | – | |
| – | – | +0.0% | +0.0% | +34.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.